Shares of AbbVie Inc. ABBV inched 0.33% higher to $191.90 Thursday, on what proved to be an all-around great trading session ...

AbbVie Inc (NYSE:ABBV) released topline results from its pivotal Phase 3 TEMPO-1 trial for tavapadon as a monotherapy in ...

A resurgence in mergers and acquisitions dealmaking is turbocharging the market for the safest US corporate debt to its ...

Tavapadon met the primary endpoint in the pivotal Phase 3, TEMPO-1 fixed-dose monotherapy trial, demonstrating a statistically significant improvement from baseline in the MDS-UPDRS Parts II and III ...

Cardurion Pharmaceuticals, Inc. ("Cardurion" or "the Company"), a clinical-stage biotechnology company developing next-generation therapeutics for the treatment of cardiovascular diseases, today ...

PARP Inhibitor Market is projected to expand substantially, surpassing USD 16,153.50 million by 2034 at a CAGR of 8.70%.

AbbVie (ABBV) said its Phase 3 trial TEMPO-1 for experimental therapy Tavapadon reached main goal in Parkinson's disease.

AbbVie plans to share results from another phase 3 trial of tavapadon later this year, the pharma said in the release. That ...

AbbVie ABBV has outperformed the market over the past 10 years by 1.46% on an annualized basis producing an average annual ...

The trial studied two doses of the drug, tavapadon, as a monotherapy in which patients showed a statistically significant ...

AbbVie reported Thursday that its experimental Parkinson’s drug that it got from Cerevel Therapeutics helped alleviate ...

Drugmaker AbbVie (ABBV) announced Thursday positive topline results from its pivotal Phase 3 TEMPO-1 trial for tavapadon as a ...